BlueRock Therapeutics

FDA grants Orphan Drug Designation to BlueRock Therapeutics’ investigational cell therapy OpCT-001

Designation is for treating retinitis pigmentosa, one of the most common types of inherited retinal disorders characterized by the loss of photoreceptor cells  OpCT-001 is an iPSC-derived investigational cell therapy being clinically tested to treat retinitis pigmentosa  Berlin, Germany, and…

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

Designation enables preferred procedural treatment and review consultation by Japan’s Ministry of Health, Labor and Welfare  Parkinson’s disease affects approximately 10 million people worldwide and 250,000 in Japan  Berlin, Germany and Cambridge, MA, USA, December 17, 2025 – Bayer AG and its…

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants   Secondary clinical efficacy endpoints related to motor outcomes remain stable compared to 24 months and continue to show positive trends from baseline   Data…

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel

BlueRock announced that the first patient has received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for Parkinson’s disease. The post First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of…

BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases

Berlin, Germany, and Cambridge, MA, USA July 8, 2025 – Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the first patient received the investigational therapy in CLARICO, a Phase 1/2a clinical […] The post…

Forging the future of cell therapy: Bayer and BlueRock’s unique journey

In this episode of The Top Line, Fierce Biotech’s Chris Hayden sat down with Dr. Juergen Eckhardt of Bayer and Dr. Seth Ettenberg of BlueRock Therapeutics to discuss an innovative partnership that’s reshaping how big pharma teams up with biotech startups. The post Forging the future of cell…